CD44 and neoplasm: In vivo xenograft tumour formation experiments revealed that the tumorigenic ability of TAK1‐overexpressing CD44+ CD133+ GC cells was significantly greater than that of CD44+ and/or CD44‐GC cells alone (Figure 4D).